Day: December 17, 2024

Americold Realty Trust, Inc. Declares Fourth Quarter 2024 Dividend

Written by Customer Service on December 17, 2024. Posted in Dividend Reports And Estimates.

ATLANTA, GA., Dec. 17, 2024 (GLOBE NEWSWIRE) — Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced that its Board of Directors has declared a dividend of $0.22 per share for the fourth quarter of 2024, payable to holders of the Company’s common stock. The dividend will be payable in cash on January 15, 2025 to stockholders of record at the close of business on December 31, 2024. About Americold Realty Trust, Inc. Americold is a global leader in temperature-controlled logistics real estate and value-added services. Focused on the ownership, operation, acquisition, and development of temperature-controlled warehouses, Americold owns and/or...

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Written by Customer Service on December 17, 2024. Posted in Public Companies.

Teva hosting investor call today at 8:00 a.m. ET (U.S.)Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussionsPARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi today announce that the Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for the treatment...

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Written by Customer Service on December 17, 2024. Posted in Public Companies.

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussions Program underscores Sanofi’s Immunology leadership ambitionParis and Parsippany, NJ, December 17, 2024. Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD assessed duvakitug, a human IgG1-λ2...

MINILUXE ANNOUNCES FRANCHISEE OPERATOR PARTNERSHIP

Written by Customer Service on December 17, 2024. Posted in Public Companies.

MiniLuxe signs agreement with respected Boston entrepreneur, Quynh Pham, who will also invest in MiniLuxe’s private placement and advise the Company on its talent recruitment. Boston, MA, Dec. 17, 2024 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX) (“MiniLuxe” or the “Company”) is pleased to announce its inaugural franchisee operator partner, Ms. Quynh Pham, a Boston-based serial retail entrepreneur and business leader. Ms. Pham will also be investing in the company’s upcoming private placement and play a role in advising the Company on the recruitment, development and retention of nail designer talent. Ms. Pham immediately begins her franchising journey with a MiniLuxe location in Brookline, Massachusetts, which is opening this week. Furthermore, over the next three years, she will invest up to $USD 2M to open three or...

REE Automotive Reports Q3 2024 Results: Reservations Surge by 230% as Production Begins and Liquidity Increases, Reaffirming BoM Breakeven Target for H2 2025

Written by Customer Service on December 17, 2024. Posted in Earnings Releases And Operating Results.

REE Automotive Q3 2024 EarningsCompany will host an earnings call on December 17, 2024 at 8:30 a.m. ET.Demand for Powered by REE vehicles surges as reservations grow by 230% to $137 million* including reservations for production that extend beyond 2025. Significant progress toward integration of REEs software defined vehicle technology (SDV) into leading OEMs in several vehicle categories. Production of flagship P7 medium duty electric truck kicked-off according to plan targeting first deliveries in H1 2025 supported by strategic partner Motherson and Detroit-based Roush Industries. Production ramp up is targeted for H2 2025 reaffirming Company’s target to reach bill-of-materials (BoM) breakeven in H2 2025 in the low hundreds of vehicles. REE’s Autonomous-ready X by-wire architecture continues to generate strong interest for...

Form 8.3 – [LOUNGERS PLC – 16 12 2024] – (CGWL)

Written by Customer Service on December 17, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LOUNGERS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 16 12 2024] – (CGWL)

Written by Customer Service on December 17, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Mustang Energy Corp. Announces Closing of First Tranche of Strategic Financing for Gross Proceeds of C$2,148,250

Written by Customer Service on December 17, 2024. Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE: MEC, OTC: MECPF, FRA: 92T) (“Mustang” or the “Company”) is pleased to announce that, pursuant to its news release of November 25, 2024, it has completed the first tranche of its non-brokered private placement for aggregate gross proceeds of C$2,148,250, pursuant to which it sold the following (together, the “Offering”):2,271,000 non-flow through common shares in the capital of the Company (each, a “Share”) at a price of C$0.25 per Share for gross proceeds of C$567,750 from the sale of the Shares; and 5,450,000 critical flow-through common shares of the Company (each, a “FT Share”, and collectively with the Shares, the “Offered Securities”) at...

Arbitration Claim Update

Written by Customer Service on December 17, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Lupaka Gold Corp. (“Lupaka” or the “Company”) (TSX-V: LPK, FRA: LQP) has received an update from the Arbitral Tribunal regarding the Company’s ongoing Arbitration Claim against the Republic of Peru. In the update, the Tribunal advised that work on the ruling has continued since the last update, and completion of the English text is nearing the final stage. Considering the time necessary to finalize the ruling for dispatch in the two procedural languages, the Tribunal presently estimates that it will be in a position to dispatch its ruling to the Parties in the course of the first quarter of 2025. Gordon Ellis (CEO) commented “Although the amount of time that the arbitration process has taken so far seems protracted, our legal counsel assures us that...

Day: December 17, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice